Do you want to read an article? Please log in or register.
Abatacept in rheumatoid arthritis: survival on drug, clinical outcomes, and their predictors-data from a large national quality register
Rheumatoid Arthritis
Related content
COMMENTED
Rheumatoid Arthritis
Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort
★ 2
Recommended and commented by
Dr Heino Prillwitz, Faculty Member
Arthritis Res Ther.
Lukas C, Mary J, Debandt M, Daïen C, Morel J, Cantagrel A, Fautrel B, Combe B
doi: 10.1186/s13075-019-2020-x.
Rheumatoid Arthritis
Flares in Rheumatoid Arthritis Patients with Low Disease Activity: Predictability and Association with Worse Clinical Outcomes
J Rheumatol.
Bechman K, Tweehuysen L, Garrood T, Scott DL, Cope AP, Galloway JB, Ma MHY
doi: 10.3899/jrheum.171375.
Rheumatoid Arthritis
Severe adverse drug reactions to biological disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis in clinical practice
Clin Exp Rheumatol.
Leon L, Gomez A, Vadillo C, Pato E, Rodriguez-Rodriguez L, Jover JA, Abasolo L
Rheumatoid Arthritis
Risk of opportunistic infections in patients with rheumatoid arthritis initiating abatacept: cumulative clinical trial data
Arthritis Res Ther
Simon TA, Dong L, Winthrop KL
doi: 10.1186/s13075-020-02399-2
Rheumatoid Arthritis
The 20 year outcome and association between early treatment and mortality and disability in an inception cohort of patients with rheumatoid arthritis: Results from the Norfolk Arthritis Register
Arthritis Rheumatol.
Gwinnutt JM, Symmons DP, MacGregor AJ, Chipping JR, Marshall T, Lunt M, Verstappen SM
doi: 10.1002/art.40090.
Rheumatoid Arthritis
Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial
JAMA.
Gottenberg JE, Brocq O, Perdriger A, Lassoued S, Berthelot JM, Wendling D, Euller-Ziegler L, Soubrier M, Richez C, Fautrel B, Constantin AL, Mariette X, Morel J, Gilson M, Cormier G, Salmon JH, Rist S, Lioté F, Marotte H, Bonnet C, Marcelli C, Sellam J, Meyer O, Solau-Gervais E, Guis S, Ziza JM, Zarnitsky C, Chary-Valckenaere I, Vittecoq O, Saraux A, Pers YM, Gayraud M, Bolla G, Claudepierre P, Ardizzone M, Dernis E, Breban MA, Fain O, Balblanc JC, Aberkane O, Vazel M, Back C, Candon S, Chatenoud L, Perrodeau E, Sibilia J, Ravaud P
doi: 10.1001/jama.2016.13512.
Rheumatoid Arthritis
2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis
Ann Rheum Dis.
Radner H, Chatzidionysiou K, Nikiphorou E, Gossec L, Hyrich KL, Zabalan C, van Eijk-Hustings Y, Williamson PR, Balanescu A, Burmester GR, Carmona L, Dougados M, Finckh A, Haugeberg G, Hetland ML, Oliver S, Porter D, Raza K, Ryan P, Santos MJ, van der Helm-van Mil A, van Riel P, von Krause G, Zavada J, Dixon WG, Askling J
doi: 10.1136/
Rheumatoid Arthritis
Safety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Orencia in Rheumatoid Arthritis Registry.
Rheumatology (Oxford).
Latourte A, Gottenberg JE, Luxembourger C, Pane I, Claudepierre P, Richette P, Lafforgue P, Combe B, Cantagrel A, Sibilia J, Flipo RM, Gaudin P, Vittecoq O, Schaeverbeke T, Dougados M, Sellam J, Ravaud P, Mariette X, Seror R
doi: 10.1093/rheumatology/kew476.
COMMENTED
Rheumatoid Arthritis
Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs
★ 3
Recommended and commented by
Dr Heino Prillwitz, Faculty Member
doi: 10.1186/s13075-019-2059-8.